Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: Effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Toblli, Jorge Eduardo ^a   Di Gennaro, Federico ^a  

^a HOSPITAL ALEMÁN   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIANEMIC AGENT; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; FERRIC CARBOXYMALTOSE; FERRITIN; HEMOGLOBIN; IRON; TRANSFERRIN; FERRIC ION; MALTOSE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; COST CONTROL; CREATININE CLEARANCE; DRUG TOLERABILITY; DRUG USE; FEMALE; FERRITIN BLOOD LEVEL; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; IRON DEFICIENCY; KIDNEY FUNCTION; MALE; MEAN CORPUSCULAR VOLUME; NON DIALYSIS CHRONIC KIDNEY DISEASE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEINURIA; TRANSFERRIN BLOOD LEVEL; TRANSFUSION; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; ERYTHROPOIESIS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RENAL INSUFFICIENCY, CHRONIC; VERY ELDERLY;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ERYTHROPOIESIS; FEMALE; FERRIC COMPOUNDS; HEMOGLOBINS; HUMANS; IRON; MALE; MALTOSE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84957818318     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125528     Document Type: Article

References (41)

1. Hsu CY, McCulloch CE, Curhan GC. Iron status and hemoglobin level in chronic renal insufficiency. J Am Soc Nephrol. 2002;13:2783-2786. PMID: 12397050
2. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, et al. Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrology Dialysis Transplantation. 2004;19:ii1-ii47.
3. McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20:1501-1510. PMID: 15383200
4. Post JB, Wilkes BM, Michelis MF. Iron deficiency in patients with chronic kidney disease: potential role for intravenous iron therapy independent of erythropoietin. Int Urol Nephrol. 2006;38:719-723. PMID: 17106764
5. Kidney disease: Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney inter, Suppl:. 2012;2:279-335.
6. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000;58:1325-1335. PMID: 10972697
7. Weiner DE, Tighiouart H, Vlagopoulos PT, Griffith JL, Salem DN, Levey AS, et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol. 2005;16:1803-1810. PMID: 15857925
8. Fishbane S, Pollack S, Feldman HI, Joffe MM. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol. 2009;4:57-61. doi: 10.2215/CJN.01670408 PMID: 18987297
9. Chang CH, Chang CC, Chiang SS. Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. Clin Nephrol. 2002;57:136-141. PMID: 11863124
10. Descombes E, Fellay G. Improved response to erythropoietin therapy with long-term continuous iron supplementation. Nephron. 2000;84:196-197. PMID: 10657727
11. DeVita MV, Frumkin D, Mittal S, Kamran A, Fishbane S, Michelis MF. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Nephrol. 2003;60:335-340. PMID: 14640239
12. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26:41-46. PMID: 7611266
13. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996;50:1694-1699. PMID: 8914038
14. Richardson D, Bartlett C, Will EJ. Optimizing erythropoietin therapy in hemodialysis patients. Am J Kidney Dis. 2001;38:109-117. PMID: 11431190
15. Schiesser D, Binet I, Tsinalis D, Dickenmann M, Keusch G, Schmidli M, et al. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. Nephrol Dial Transplant. 2006;21:2841-2845. PMID: 16891647
16. Sepandj F, Jindal K, West M, Hirsch D. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant. 1996;11:319-322. PMID: 8671786
17. Li H, Wang SX. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Blood Purif. 2008;26:151-156. doi: 10.1159/000113529 PMID: 18212498
18. Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005;100:c55-c62. PMID: 15824508
19. Mircescu G, Garneata L, Capusa C, Ursea N. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant. 2006;21:120-124. PMID: 16144853
20. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant. 2011;26:1599-1607. doi: 10.1093/ndt/gfq613 PMID: 20929915
21. Silverberg DS, Iaina A, Peer G, Kaplan E, Levi BA, Frank N, et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis. 1996;27:234-238. PMID: 8659499
22. Silverberg DS, Blum M, Agbaria Z, Deutsch V, Irony M, Schwartz D, et al. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clin Nephrol. 2001;55:212-219. PMID: 11316241
23. Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant. 2001;16:967-974. PMID: 11328902
24. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005;68:2846-2856. PMID: 16316362
25. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis. 2008;52:897-906. doi: 10.1053/j.ajkd.2008.05.033 PMID: 18845368
26. Macdougall IC, Bock A, Carrera F, Eckardt KU, Gaillard C, Van WD, et al. The FIND-CKD study: a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale. Nephrol Dial Transplant. 2014;29:843-850. doi: 10.1093/ndt/gft424 PMID: 24170814
27. Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl:. 1999;69:S61-S66.
28. Macdougall IC, Chandler G, Elston O, Harchowal J. Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. Am J Kidney Dis. 1999;34:S40-S46. PMID: 10516375
29. Luporsi E, Mahi L, Morre C, Wernli J, de PG, Bugat R. Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective. J Med Econ. 2012;15:225-232. doi: 10.3111/13696998.2011. 639823 PMID: 22077267
30. Hedenus M, Birgegard G, Nasman P, Ahlberg L, Karlsson T, Lauri B, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia. 2007;21:627-632. PMID: 17252006
31. Szucs TD, Blank P, Schwenkglenks M, Aapro M. Potential health economic impact of i.v. iron supplementation to ESA treatment in patients with cancer- or chemotherapy-induced anaemia. Oncology. 2011;81:45-49. doi: 10.1159/000330738 PMID: 21921645
32. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-2084. PMID: 17108342
33. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de ZD, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019-2032. doi: 10.1056/NEJMoa0907845 PMID: 19880844
34. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-2098. PMID: 17108343
35. Anker SD, Comin CJ, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436-2448. doi: 10.1056/NEJMoa0908355 PMID: 19920054
36. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. European Heart Journal. 2015;36:657-668. doi: 10.1093/eurheartj/ehu385 PMID: 25176939
37. Kulnigg-Dabsch S, Schmid W, Howaldt S, Stein J, Mickisch O, Waldhor T, et al. Iron Deficiency Generates Secondary Thrombocytosis and Platelet Activation in IBD: the Randomized, Controlled Thrombo-VIT Trial. Inflamm Bowel Dis. 2013;19:1609-1616. doi: 10.1097/MIB.0b013e318281f4db PMID: 23644823
38. Kulnigg-Dabsch S, Evstatiev R, Dejaco C, Gasche C. Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia. PLoS One. 2012;7:e34520. doi: 10.1371/journal.pone.0034520 PMID: 22506024
39. Favrat B, Balck K, Breymann C, Hedenus M, Keller T, Mezzacasa A, et al. Evaluation of a Single Dose of Ferric Carboxymaltose in Fatigued, Iron-Deficient Women-PREFER a Randomized, Placebo-Controlled Study. PLoS One. 2014;9:e94217. doi: 10.1371/journal.pone.0094217 PMID: 24751822
40. Aapro M, Osterborg A, Gascon P, Ludwig H, Beguin Y. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of intravenous iron. Ann Oncol. 2012;23:1954-1962. doi: 10.1093/annonc/mds112 PMID: 22575608
41. Munoz M, Martin-Montanez E. Ferric carboxymaltose for the treatment of iron-deficiency anemia. [corrected]. Expert Opin Pharmacother. 2012;13:907-921. doi: 10.1517/14656566.2012.669373 PMID: 22413903